PureTech Launches Phase 2 Trial of LYT-100 in IPF Patients
PureTech has initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). “We are excited to be taking this important step towards our goal of helping patients with this devastating condition,” Julie Krop, MD, PureTech’s chief…